Full Text View
Tabular View
Study Results
Related Studies
Demonstrating the Clinical and Economic Benefit of 5 Alpha Reductase Inhibitor Adherence in Benign Prostatic Hyperplasia
This study has been completed.
Study NCT01334723   Information provided by GlaxoSmithKline

First Received on April 7, 2011.   Last Updated on December 8, 2011   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Prostatic Hyperplasia
Additional conditions recognized in this trial
Hyperplasia
More general conditions related to this trial
Genital Diseases, Male
Pathologic Processes
Prostatic Diseases
Interventions listed in this trial
Non-adherent to 5ARI therapy
Additional drug interventions recognized in this trial
5-alpha Reductase Inhibitors
More general drug interventions related to this trial
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Sponsors listed in this trial
GlaxoSmithKline


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services